Genomtec S.A.

Regulatory Filings • Jul 7, 2021

Patent filing application for the proprietary set of primers, diagnosticmethod and the reaction mixture composition to genetically diagnoseNeisseria Meningitidis in LAMP technique.Management Board ofGenomtec S.A. (The "Issuer") informs that as of today, i.e. on July 7,2021, a patent application has been filed for the technology developedby the Issuer.The described application concerns the proprietaryset of primers, the diagnostic method and the reaction mixturecomposition for the genetic diagnosis of Neisseria Meningitidis in theLAMP technique. The application was filed with the Polish Patent Office,Republic of Poland.Neisseria Meningitidis is a species ofgram-negative bacteria that causes meningitis and meningococcal sepsis.This bacterium is of great concern because infections can occur not onlyin the form of sporadic, endemic, hyperendemic, but also epidemic andpandemic diseases. In order to successfully treat meningococcalinfection, prompt diagnosis is very important as the disease progressesvery quickly.The developed set of primers is a key element ofthe diagnostic method based on the LAMP technology utilized by theIssuer. Primers initiate the amplification reaction by recognizing aspecific fragment of the pathogen's genome. The described patentapplication prevents the risk of using the same set of primers in anassay by competitors.The Issuer's Management Board decided thatfiling the described patent application is a confidential information,as for an entity operating on the molecular diagnostics market it isnecessary to effectively protect intellectual property and designs.Properly secured intellectual property and designs may constitute theIssuer's competitive advantage, allowing safer commercialization undercondition that full protection is ensured on selected markets.Inthe opinion of the Management Board, a high level of intellectualproperty protection will also provide the Company with a n advantageousnegotiating position before signing any commercial contracts withselected partners as part of the commercialization strategyimplementation.Diagnosis of bacterial infections, includingNeisseria Meningitidis, is one of the key areas of technology developedby the Issuer. For these reasons, in the opinion of the ManagementBoard, this information meets the criteria of confidential informationdescribed in Art. 7 sec. 1 MAR.